2 completed, 1 active not recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
Follow XmAb24306: new trials by email Literature Review of XmAb24306 trials Research Report on XmAb24306
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma Cevostamab, XmAb24306, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 90 | 2023-03-21 | 2026-08-11 |
| A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma XmAb24306, Daratumumab - Multiple Myeloma | Phase 1 | Completed | Genentech, Inc. | 18 | 2022-04-28 | 2025-02-17 |
| An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors XmAb24306, Atezolizumab - Solid Tumors | Phase 1 | Completed | Genentech, Inc. | 195 | 2020-03-09 | 2026-07-02 |
Multiple Myeloma (2)
Genentech, Inc. (3)
Australia (3) · Spain (3) · Denmark (2) · Norway (2) · South Korea (2) · Belgium (1) · Brazil (1) · Canada (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · United States (1)
2023 (1)